Skip to main content
Johnson & JohnsonInvestment

Johnson & Johnson Stock: New Investments in Cancer and Psychiatry

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson agreed to an investment in Francis Medical.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Johnson & Johnson is expanding its strategic reach in oncology and psychiatry. According to Yahoo Finance on Thursday, November 12, the healthcare group agreed to an investment in Francis Medical while also leading a 100 million US dollar financing round for Delix Therapeutics. Francis Medical is developing Vanquish, a minimally invasive device for the treatment of prostate cancer. The investment complements Johnson & Johnson's existing activities in this disease area, which also include the bispecific agents pasritamig and JNJ-9401. Vanquish targets localized prostate cancer, while the drug programs address advanced diseases. The company is thus further broadening its activities from local treatment to systemic therapy. For investors, the transaction is primarily a strategic addition with a longer time horizon. The device is still in the development phase, so the investment will not result in a significant revenue contribution in the short term. Clinical progress, regulatory steps, and subsequent healthcare reimbursement will be decisive. The financing round at Delix Therapeutics, led by Johnson & Johnson, is intended to fund clinical programs for psychedelically inspired depression therapies. According to the company, the drug candidates aim to rely on new treatment approaches without triggering the hallucinations typical of classic psychedelics. The investment thus...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Investment

What this signalsAn investment often shows where the company plans to grow.

Takes effect
Nov 12, 2026

Companies

  • Francis MedicalRelated companyfrancismedical.com

More investment signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 13, 2026
signal_type
news
signal_subtype
invests_into

Use this data

Get every investment signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns investment signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0a539f0a-9ddc-8e72-6063-97d225ce0d89 returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "0a539f0a-9ddc-8e72-6063-97d225ce0d89",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-11-13T12:41:19+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/johnson-johnson-aktie-neue-investitionen-in-krebs-und-psychiatrie/70504723",
    "title": "Johnson & Johnson Stock: New Investments in Cancer and Psychiatry - ad-hoc-news.de",
    "excerpt": "Johnson & Johnson is expanding its strategic reach in oncology and psychiatry. According to Yahoo Finance on Thursday, November 12, the healthcare group agreed to an investment in Francis Medical while also leading a 100 million US dollar financing round for Delix Therapeutics. Francis Medical is developing Vanquish, a minimally invasive device for the treatment of prostate cancer. The investment complements Johnson & Johnson's existing activities in this disease area, which also include the bispecific agents pasritamig and JNJ-9401. Vanquish targets localized prostate cancer, while the drug programs address advanced diseases. The company is thus further broadening its activities from local treatment to systemic therapy. For investors, the transaction is primarily a strategic addition with a longer time horizon. The device is still in the development phase, so the investment will not result in a significant revenue contribution in the short term. Clinical progress, regulatory steps, and subsequent healthcare reimbursement will be decisive. The financing round at Delix Therapeutics, led by Johnson & Johnson, is intended to fund clinical programs for psychedelically inspired depression therapies. According to the company, the drug candidates aim to rely on new treatment approaches without triggering the hallucinations typical of classic psychedelics. The investment thus expands...",
    "summary": "Johnson & Johnson agreed to an investment in Francis Medical.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2698398_1200_675.webp",
    "confidence": 0.95,
    "published_at": "2026-11-13T12:41:19Z",
    "effective_date": "2026-11-12",
    "article_sentence": "According to Yahoo Finance on Thursday, November 12, the healthcare group agreed to an investment in Francis Medical while also leading a 100 million US dollar financing round for Delix Therapeutics.",
    "related_company_name": "Francis Medical",
    "related_company_domain": "francismedical.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.